Trials / Completed
CompletedNCT03066011
Registry of Patients Treated With Systemic Mold-Active Triazoles
Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,015 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Isavuconazonium sulfate | Oral and Intravenous |
| DRUG | Voriconazole | Oral and Intravenous |
| DRUG | Posaconazole | Oral and intravenous |
Timeline
- Start date
- 2017-03-16
- Primary completion
- 2020-04-24
- Completion
- 2020-04-24
- First posted
- 2017-02-28
- Last updated
- 2024-10-21
Locations
56 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03066011. Inclusion in this directory is not an endorsement.